According to the latest report by IMARC Group “Human Insulin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026“, The global human insulin market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 5% during 2021-2026.
Human insulin (HI) is a short-acting insulin that is synthesized in laboratories. Commonly utilized to mimic the function of natural insulin present in humans, it is bio-engineered by growing insulin proteins within E-coli bacteria (Escherichia coli). It is available as a solution and suspension and is required to be injected subcutaneously. It is widely employed for controlling the blood sugar levels of patients with type I and II diabetes.
HI functions by aiding the sugar produced by the human body to move from the blood to other body tissues where it is used for energy. It can additionally stop the liver from producing more sugar. Apart from this, HI also assists in inhibiting hepatic glucose production and improving the protein synthesis of the body.
The growing prevalence of obesity and diabetes among individuals due to sedentary lifestyles represents one of the key factors driving the market. Apart from this, there is a significant rise in the demand for biosimilar drugs on account of their cost-effectiveness and higher efficiency, which, in turn, is also supporting the growth of the market. Furthermore, the key players are introducing pen devices and safety pen needles for improved delivery of insulin to the body. This, in confluence with the increasing research and development (R&D) activities, is acting as another growth-inducing factor.
Request for a free sample copy of this report: https://www.imarcgroup.com/human-insulin-market/requestsample
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
Some of these key players include:
- B. Braun Melsungen AG
- Becton Dickinson & Company
- Eli Lilly and Company
- Novo Nordisk
- Ypsomed Holding, etc.
Explore full report with table of contents: https://www.imarcgroup.com/human-insulin-market
The report has segmented the market on the basis of Product Type, End-User and Region.
Breakup by Product Type:
- Human Insulin Analogs and Biosimilars
- Rapid Acting
- Long Acting
- Human Insulin Biologics
- Short Acting
- Intermediate Acting
- Human Insulin Analogs and Biosimilars
- Delivery Devices
- Reusable Pens
- Disposable Pens
- Pen Needles
- Standard Pen Needles
- Safety Pen Needles
Breakup by Distribution Channel:
- Retail Pharmacies
- Hospital Pharmacies
- Online Retail Stores
Breakup by Disease Type:
- Type I Diabetes
- Type II Diabetes
Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
If you want latest primary and secondary data (2021-2026) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800